

**Spine Biologics Market By Product (Spinal Allografts, Bone Graft Substitutes, Cell-Based Matrix) , By End User (Hospitals, Outpatient Facilities) : Global Opportunity Analysis and Industry Forecast, 2024-2033**

Market Report | 2024-07-01 | 280 pages | Allied Market Research

**AVAILABLE LICENSES:**

- Cloud Access License \$2389.50
- Business User License \$3599.10
- Enterprise License \$6670.80

**Report description:**

Spine Biologics Market□

The spine biologics market was valued at \$3.05 billion in 2023 and is estimated to reach \$5.55 billion by 2035, exhibiting a CAGR of 5.29% from 2024 to 2035.□

Spine biologics comprises of materials that enhance spinal fusion, promote healing, and treat several spinal disorders. The materials involve growth factors, stem cells, and bone grafts, which help in the natural healing processes of the body. Bone grafts are the scaffolds required for new bone growth. They include autografts, which belong to patient's own body, and allografts, which are derived from a donor. Stem cells are a special form of cells that have the ability to generate new cells with complete functionalities and growth factors, such as bone morphogenetic proteins (BMPs), play role in stimulating the cells for regeneration and bone repair. The usage of spine biologics is widespread in spinal fusion surgeries, which involve the joining of two or more vertebrae.□

Increase in the prevalence of spinal disorders, particularly in the exponentially growing geriatric population, is a key driver of the spine biologics market. In addition, with rising inclination toward minimally invasive procedures, the demand for spine biologics is surging as they facilitate minimal invasion during spinal surgeries and promote healing. In recent times, the use of additive manufacturing for the development of bone graft substitute is an emerging trend in the market. These substitutes offer equivalent efficacy and improved safety when compared to bone grafts, which hold the potential for rejection by the body.□

However, the development of spine biologics is a complex procedure with high expenses, hence restraining the development of the market. Furthermore, the ineffective reimbursement policies that do not offer adequate cover for spinal surgeries deter individuals from undergoing expensive treatments, hence limiting the market growth. On the contrary, the consistently rising numbers of spinal injuries are anticipated to propel the demand for spine biologics in the future. The National Library of Medicine recently published an article which reported that every year 38% of new spinal cord injuries occur due to motor vehicular crashes

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

in the U.S. falling is the second most prevalent reason for spinal injuries, accounting for 30% of the total count.□

#### Segment Review□

The spine biologics market is segmented into product, end user, and region. By product, the market is divided into spinal allografts, bone graft substitutes, and cell-based matrix. As per end user, it is bifurcated into hospitals and outpatient facilities. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.□

#### Key Findings□

By product, the spinal allografts segment dominated the market in 2023.□

As per end user, the hospital segment acquired a high stake in the market in 2023.□

Region wise, North America is projected to be the highest revenue generator by 2035.□

#### Competition Analysis□

The major players operating in the spine biologics market are Stryker, NuVasive, Inc., Orthofix, Johnson & Johnson, Exactech, Inc., Zimmer Biomet. Arthrex, Inc., Medtronic Plc, Organogenesis Inc., and Kuros Biosciences. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

□

Additional benefits you will get with this purchase are:

- Quarterly Update and\* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support\* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization\* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response\*
- Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)

#### Key Market Segments

##### By Product

- Spinal Allografts
- Bone Graft Substitutes
- Cell-Based Matrix

##### By End User

- Hospitals
- Outpatient Facilities

##### By Region

- North America
- U.S.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Stryker Corporation
- NuVasive, Inc.
- orthofix
- Johnson & Johnson
- Exactech, Inc
- Zimmer Biomet Holding, Inc.
- Arthrex, Inc.
- Medtronic plc
- Organogenesis Inc
- Kuros Biosciences

## **Table of Contents:**

### CHAPTER 1: INTRODUCTION

- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
  - 1.4.1. Primary Research
  - 1.4.2. Secondary Research
  - 1.4.3. Analyst Tools and Models

### CHAPTER 2: EXECUTIVE SUMMARY

- 2.1. CXO Perspective

### CHAPTER 3: MARKET LANDSCAPE

- 3.1. Market Definition and Scope
- 3.2. Key Findings

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
  - 3.3.1. Bargaining Power of Suppliers
  - 3.3.2. Threat of New Entrants
  - 3.3.3. Threat of Substitutes
  - 3.3.4. Competitive Rivalry
  - 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
  - 3.4.1. Drivers
  - 3.4.2. Restraints
  - 3.4.3. Opportunities
- CHAPTER 4: IMMUNOHEMATOLOGY MARKET, BY PRODUCT
  - 4.1. Market Overview
    - 4.1.1 Market Size and Forecast, By Product
  - 4.2. Analyzers And Systems
    - 4.2.1. Key Market Trends, Growth Factors and Opportunities
    - 4.2.2. Market Size and Forecast, By Region
    - 4.2.3. Market Share Analysis, By Country
  - 4.3. Reagents
    - 4.3.1. Key Market Trends, Growth Factors and Opportunities
    - 4.3.2. Market Size and Forecast, By Region
    - 4.3.3. Market Share Analysis, By Country
- CHAPTER 5: IMMUNOHEMATOLOGY MARKET, BY APPLICATION
  - 5.1. Market Overview
    - 5.1.1 Market Size and Forecast, By Application
  - 5.2. Blood-related Diseases
    - 5.2.1. Key Market Trends, Growth Factors and Opportunities
    - 5.2.2. Market Size and Forecast, By Region
    - 5.2.3. Market Share Analysis, By Country
  - 5.3. HIV
    - 5.3.1. Key Market Trends, Growth Factors and Opportunities
    - 5.3.2. Market Size and Forecast, By Region
    - 5.3.3. Market Share Analysis, By Country
  - 5.4. Others
    - 5.4.1. Key Market Trends, Growth Factors and Opportunities
    - 5.4.2. Market Size and Forecast, By Region
    - 5.4.3. Market Share Analysis, By Country
- CHAPTER 6: IMMUNOHEMATOLOGY MARKET, BY END USER
  - 6.1. Market Overview
    - 6.1.1 Market Size and Forecast, By End User
  - 6.2. Hospitals
    - 6.2.1. Key Market Trends, Growth Factors and Opportunities
    - 6.2.2. Market Size and Forecast, By Region
    - 6.2.3. Market Share Analysis, By Country
  - 6.3. Diagnostic Laboratories
    - 6.3.1. Key Market Trends, Growth Factors and Opportunities

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
- 6.4. Others
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country

## CHAPTER 7: IMMUNOHEMATOLOGY MARKET, BY REGION

- 7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
- 7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Product
- 7.2.3. Market Size and Forecast, By Application
- 7.2.4. Market Size and Forecast, By End User
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Immunohematology Market
- 7.2.6.1. Market Size and Forecast, By Product
- 7.2.6.2. Market Size and Forecast, By Application
- 7.2.6.3. Market Size and Forecast, By End User
- 7.2.7. Canada Immunohematology Market
- 7.2.7.1. Market Size and Forecast, By Product
- 7.2.7.2. Market Size and Forecast, By Application
- 7.2.7.3. Market Size and Forecast, By End User
- 7.2.8. Mexico Immunohematology Market
- 7.2.8.1. Market Size and Forecast, By Product
- 7.2.8.2. Market Size and Forecast, By Application
- 7.2.8.3. Market Size and Forecast, By End User
- 7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Product
- 7.3.3. Market Size and Forecast, By Application
- 7.3.4. Market Size and Forecast, By End User
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. Germany Immunohematology Market
- 7.3.6.1. Market Size and Forecast, By Product
- 7.3.6.2. Market Size and Forecast, By Application
- 7.3.6.3. Market Size and Forecast, By End User
- 7.3.7. France Immunohematology Market
- 7.3.7.1. Market Size and Forecast, By Product
- 7.3.7.2. Market Size and Forecast, By Application
- 7.3.7.3. Market Size and Forecast, By End User
- 7.3.8. UK Immunohematology Market
- 7.3.8.1. Market Size and Forecast, By Product
- 7.3.8.2. Market Size and Forecast, By Application
- 7.3.8.3. Market Size and Forecast, By End User
- 7.3.9. Italy Immunohematology Market
- 7.3.9.1. Market Size and Forecast, By Product

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 7.3.9.2. Market Size and Forecast, By Application
- 7.3.9.3. Market Size and Forecast, By End User
- 7.3.10. Spain Immunohematology Market
  - 7.3.10.1. Market Size and Forecast, By Product
  - 7.3.10.2. Market Size and Forecast, By Application
  - 7.3.10.3. Market Size and Forecast, By End User
- 7.3.11. Rest of Europe Immunohematology Market
  - 7.3.11.1. Market Size and Forecast, By Product
  - 7.3.11.2. Market Size and Forecast, By Application
  - 7.3.11.3. Market Size and Forecast, By End User
- 7.4. Asia-Pacific
  - 7.4.1. Key Market Trends and Opportunities
  - 7.4.2. Market Size and Forecast, By Product
  - 7.4.3. Market Size and Forecast, By Application
  - 7.4.4. Market Size and Forecast, By End User
  - 7.4.5. Market Size and Forecast, By Country
  - 7.4.6. Japan Immunohematology Market
    - 7.4.6.1. Market Size and Forecast, By Product
    - 7.4.6.2. Market Size and Forecast, By Application
    - 7.4.6.3. Market Size and Forecast, By End User
  - 7.4.7. China Immunohematology Market
    - 7.4.7.1. Market Size and Forecast, By Product
    - 7.4.7.2. Market Size and Forecast, By Application
    - 7.4.7.3. Market Size and Forecast, By End User
  - 7.4.8. India Immunohematology Market
    - 7.4.8.1. Market Size and Forecast, By Product
    - 7.4.8.2. Market Size and Forecast, By Application
    - 7.4.8.3. Market Size and Forecast, By End User
  - 7.4.9. Australia Immunohematology Market
    - 7.4.9.1. Market Size and Forecast, By Product
    - 7.4.9.2. Market Size and Forecast, By Application
    - 7.4.9.3. Market Size and Forecast, By End User
  - 7.4.10. South Korea Immunohematology Market
    - 7.4.10.1. Market Size and Forecast, By Product
    - 7.4.10.2. Market Size and Forecast, By Application
    - 7.4.10.3. Market Size and Forecast, By End User
  - 7.4.11. Rest of Asia-Pacific Immunohematology Market
    - 7.4.11.1. Market Size and Forecast, By Product
    - 7.4.11.2. Market Size and Forecast, By Application
    - 7.4.11.3. Market Size and Forecast, By End User
- 7.5. LAMEA
  - 7.5.1. Key Market Trends and Opportunities
  - 7.5.2. Market Size and Forecast, By Product
  - 7.5.3. Market Size and Forecast, By Application
  - 7.5.4. Market Size and Forecast, By End User
  - 7.5.5. Market Size and Forecast, By Country
  - 7.5.6. Brazil Immunohematology Market

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 7.5.6.1. Market Size and Forecast, By Product
- 7.5.6.2. Market Size and Forecast, By Application
- 7.5.6.3. Market Size and Forecast, By End User
- 7.5.7. Saudi Arabia Immunohematology Market
  - 7.5.7.1. Market Size and Forecast, By Product
  - 7.5.7.2. Market Size and Forecast, By Application
  - 7.5.7.3. Market Size and Forecast, By End User
- 7.5.8. South Africa Immunohematology Market
  - 7.5.8.1. Market Size and Forecast, By Product
  - 7.5.8.2. Market Size and Forecast, By Application
  - 7.5.8.3. Market Size and Forecast, By End User
- 7.5.9. Rest of LAMEA Immunohematology Market
  - 7.5.9.1. Market Size and Forecast, By Product
  - 7.5.9.2. Market Size and Forecast, By Application
  - 7.5.9.3. Market Size and Forecast, By End User

## CHAPTER 8: COMPETITIVE LANDSCAPE

- 8.1. Introduction
- 8.2. Top Winning Strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top Player Positioning, 2023

## CHAPTER 9: COMPANY PROFILES

- 9.1. Bio-Rad Laboratories, Inc
  - 9.1.1. Company Overview
  - 9.1.2. Key Executives
  - 9.1.3. Company Snapshot
  - 9.1.4. Operating Business Segments
  - 9.1.5. Product Portfolio
  - 9.1.6. Business Performance
  - 9.1.7. Key Strategic Moves and Developments
- 9.2. Werfen
  - 9.2.1. Company Overview
  - 9.2.2. Key Executives
  - 9.2.3. Company Snapshot
  - 9.2.4. Operating Business Segments
  - 9.2.5. Product Portfolio
  - 9.2.6. Business Performance
  - 9.2.7. Key Strategic Moves and Developments
- 9.3. Grifols, S.A.
  - 9.3.1. Company Overview
  - 9.3.2. Key Executives
  - 9.3.3. Company Snapshot
  - 9.3.4. Operating Business Segments
  - 9.3.5. Product Portfolio
  - 9.3.6. Business Performance
  - 9.3.7. Key Strategic Moves and Developments

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9.4. Danaher Corporation
  - 9.4.1. Company Overview
  - 9.4.2. Key Executives
  - 9.4.3. Company Snapshot
  - 9.4.4. Operating Business Segments
  - 9.4.5. Product Portfolio
  - 9.4.6. Business Performance
  - 9.4.7. Key Strategic Moves and Developments
- 9.5. Siemens
  - 9.5.1. Company Overview
  - 9.5.2. Key Executives
  - 9.5.3. Company Snapshot
  - 9.5.4. Operating Business Segments
  - 9.5.5. Product Portfolio
  - 9.5.6. Business Performance
  - 9.5.7. Key Strategic Moves and Developments
- 9.6. Thermo Fisher Scientific Inc.
  - 9.6.1. Company Overview
  - 9.6.2. Key Executives
  - 9.6.3. Company Snapshot
  - 9.6.4. Operating Business Segments
  - 9.6.5. Product Portfolio
  - 9.6.6. Business Performance
  - 9.6.7. Key Strategic Moves and Developments
- 9.7. Abbott Laboratories
  - 9.7.1. Company Overview
  - 9.7.2. Key Executives
  - 9.7.3. Company Snapshot
  - 9.7.4. Operating Business Segments
  - 9.7.5. Product Portfolio
  - 9.7.6. Business Performance
  - 9.7.7. Key Strategic Moves and Developments
- 9.8. Merck KGaA
  - 9.8.1. Company Overview
  - 9.8.2. Key Executives
  - 9.8.3. Company Snapshot
  - 9.8.4. Operating Business Segments
  - 9.8.5. Product Portfolio
  - 9.8.6. Business Performance
  - 9.8.7. Key Strategic Moves and Developments
- 9.9. F. Hoffmann-La Roche Ltd
  - 9.9.1. Company Overview
  - 9.9.2. Key Executives
  - 9.9.3. Company Snapshot
  - 9.9.4. Operating Business Segments
  - 9.9.5. Product Portfolio
  - 9.9.6. Business Performance

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)



- 9.9.7. Key Strategic Moves and Developments
- 9.10. Cardinal Health
  - 9.10.1. Company Overview
  - 9.10.2. Key Executives
  - 9.10.3. Company Snapshot
  - 9.10.4. Operating Business Segments
  - 9.10.5. Product Portfolio
  - 9.10.6. Business Performance
  - 9.10.7. Key Strategic Moves and Developments

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Spine Biologics Market By Product (Spinal Allografts, Bone Graft Substitutes, Cell-Based Matrix) , By End User (Hospitals, Outpatient Facilities) : Global Opportunity Analysis and Industry Forecast, 2024-2033**

Market Report | 2024-07-01 | 280 pages | Allied Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Cloud Access License	\$2389.50
	Business User License	\$3599.10
	Enterprise License	\$6670.80
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ \*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-06"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Signature

A large, empty rectangular box with a thin black border, intended for a signature.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)